Page 1

May 13 , 2021 CYMABAY THERAPEUTICS CymaBay Reports First Quarter 2021 Financial Results and Provides Corporate Update Highly experienced executives , Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer , strengthen the management team Biopharma leaders , Thomas Wiggans and Janet Dorling , appointed to the Board of Directors Actively recruiting patients in two global , clinical studies evaluating seladelpar in primary biliary cholangitis ( PBC ) : ● RESPONSE , a 52 - week , randomized , placebo - controlled , Phase 3 registrational study • ASSURE , an open - label , long - term study Two pipeline programs also in clinical development : • Phase 2a study of MBX - 2982 , a GPR119 agonist , for the prevention of diabetic hypoglycemia • Phase 1 pharmacokinetic study of CB - 0406 , a non - agonist ligand of PPARg , for inflammation and fibrosis Conference call and webcast today at 4:30 p.m. ET NEWARK , Calif . , May 13 , 2021 ( GLOBE NEWSWIRE ) -- CymaBay Therapeutics , Inc. ( NASDAQ : CBAY ) , a clinical - stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need , today announced corporate updates and financial results for the first quarter ended March 31 , 2021 . In May 2021 , CymaBay strengthened its management team with the additions of Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer . CymaBay also continued to make significant progress conducting the development program for seladelpar in primary biliary cholangitis ( PBC ) . With clinical sites activated in North America and Europe , patient recruitment is underway in RESPONSE , a global Phase 3 registrational study evaluating seladelpar in patients with PBC . In addition , CymaBay continued to conduct enrollment activities for ASSURE , an open - label , long - term study of seladelpar in patients with PBC intended to collect additional safety data to support registration . Sujal Shah , President and CEO of CymaBay , stated , " I'm excited to announce the addition of two key executives to our management team , Dr. Dennis Kim as Chief Medical Officer and Lewis Stuart as Chief Commercial Officer . Dennis and Lewis are both experienced biopharma industry executives who will further complement our team and provide leadership